NorthSea Therapeutics Strengthens Its Management Team With the Appointment Of Mats Blom As CFO
Summary
NAARDEN, The Netherlands--(BUSINESS WIRE)--NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of Mats Blom as Chief Financial Officer (CFO). Mr Blom joined NorthSea Therapeutics on 3 September 2019, and brings significant experience, having worked in senior financial management roles for both public and private life sciences companies. I am looking forward to joining such a strong team and contributing to the Company’s future success.” NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of inflammatory, metabolic and liver diseases. NST licensed the rights to its lead compound icosabutate and a library of discovery- and pre-clinical-stage SEFAs from Pronova BioPharma Norge AS, who developed Omacor®, a blockbuster cardiovascular drug. An estimated 15 – 30% of the adult population in developed countries have NAFLD, 10 – 15% of whom may advance to NASH representing at least ~15 – 30 million patients in the 6 major markets.